199 related articles for article (PubMed ID: 8263847)
1. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma.
Keller ET; MacEwen EG; Rosenthal RC; Helfand SC; Fox LE
J Vet Intern Med; 1993; 7(5):289-95. PubMed ID: 8263847
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
Garrett LD; Thamm DH; Chun R; Dudley R; Vail DM
J Vet Intern Med; 2002; 16(6):704-9. PubMed ID: 12465768
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma.
Myers NC; Moore AS; Rand WM; Gliatto J; Cotter SM
J Vet Intern Med; 1997; 11(6):333-9. PubMed ID: 9470157
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
Simon D; Moreno SN; Hirschberger J; Moritz A; Kohn B; Neumann S; Jurina K; Scharvogel S; Schwedes C; Reinacher M; Beyerbach M; Nolte I
J Am Vet Med Assoc; 2008 Mar; 232(6):879-85. PubMed ID: 18341445
[TBL] [Abstract][Full Text] [Related]
8. Histologic classification as an indication of therapeutic response in malignant lymphoma of dogs.
Gray KN; Raulston GL; Gleiser CA; Jardine JH
J Am Vet Med Assoc; 1984 Apr; 184(7):814-7. PubMed ID: 6725115
[TBL] [Abstract][Full Text] [Related]
9. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?
Hahn KA; Richardson RC; Teclaw RF; Cline JM; Carlton WW; DeNicola DB; Bonney PL
J Vet Intern Med; 1992; 6(1):3-10. PubMed ID: 1548624
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing first remission and survival in 145 dogs with lymphoma: a retrospective study.
Baskin CR; Couto CG; Wittum TE
J Am Anim Hosp Assoc; 2000; 36(5):404-9. PubMed ID: 10997515
[TBL] [Abstract][Full Text] [Related]
11. Treatment of canine lymphoma with COPLA/LVP.
Boyce KL; Kitchell BE
J Am Anim Hosp Assoc; 2000; 36(5):395-403. PubMed ID: 10997514
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.
Siedlecki CT; Kass PH; Jakubiak MJ; Dank G; Lyons J; Kent MS
Can Vet J; 2006 Jan; 47(1):52-9. PubMed ID: 16536229
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
14. Are B-symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B-cell lymphoma.
Škor O; Bicanová L; Wolfesberger B; Fuchs-Baumgartinger A; Ruetgen B; Štěrbová M; Schwendenwein I; Kleiter M
Vet Comp Oncol; 2021 Mar; 19(1):201-208. PubMed ID: 33136315
[TBL] [Abstract][Full Text] [Related]
15. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
Simon D; Nolte I; Eberle N; Abbrederis N; Killich M; Hirschberger J
J Vet Intern Med; 2006; 20(4):948-54. PubMed ID: 16955821
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs.
Rassnick KM; Moore AS; Collister KE; Northrup NC; Kristal O; Chretin JD; Bailey DB
J Vet Intern Med; 2009; 23(2):317-22. PubMed ID: 19192147
[TBL] [Abstract][Full Text] [Related]
17. Assessment of corticosteroid-induced alkaline phosphatase as a prognostic indicator in canine lymphoma.
Wiedemann AL; Charney SC; Barger AM; Schaeffer DJ; Kitchell BE
J Small Anim Pract; 2005 Apr; 46(4):185-90. PubMed ID: 15835237
[TBL] [Abstract][Full Text] [Related]
18. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
Zemann BI; Moore AS; Rand WM; Mason G; Ruslander DM; Frimberger AE; Wood CA; L'Heureux DA; Gliatto J; Cotter SM
J Vet Intern Med; 1998; 12(6):465-70. PubMed ID: 9857340
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma.
Moore AS; Cotter SM; Rand WM; Wood CA; Williams LE; London CA; Frimberger AE; L'Heureux DA
J Vet Intern Med; 2001; 15(4):348-54. PubMed ID: 11467592
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma.
Piek CJ; Rutteman GR; Teske E
Vet Q; 1999 Apr; 21(2):44-9. PubMed ID: 10321012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
